Patents by Inventor Marco Springer

Marco Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1
    Patent number: 10815455
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 27, 2020
    Assignee: Vaximm AG
    Inventors: Heinz Lubenau, Marco Springer
  • MSLN targeting DNA vaccine for cancer immunotherapy
    Patent number: 10441645
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 15, 2019
    Assignee: VAXIMM GMBH
    Inventors: Marco Springer, Heinz Lubenau
  • SALMONELLA-BASED VECTORS FOR CANCER IMMUNOTHERAPY TARGETING WILMS' TUMOR GENE WT1
    Publication number: 20180163169
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: January 16, 2018
    Publication date: June 14, 2018
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • -based vectors for cancer immunotherapy targeting wilms' tumor gene WT1
    Patent number: 9920297
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 20, 2018
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Marco Springer
  • NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20180064794
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 8, 2018
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • Method for producing high yield attenuated strains
    Patent number: 9493738
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 15, 2016
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317634
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Vaximm GMBH Mafinex-Technologiezentrum
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • SALMONELLA-BASED VECTORS FOR CANCER IMMUNOTHERAPY TARGETING WILMS' TUMOR GENE WT1
    Publication number: 20160068801
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 10, 2016
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • Method for Producing High Yield Attenuated Salmonella Strains
    Publication number: 20140349274
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 27, 2014
    Applicant: Vaximm AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • BIORESORBABLE, MINERALISED MATERIAL FOR FILLING OSSEOUS DEFECTS
    Publication number: 20090216336
    Abstract: A bioresorbable and mineralized material for filling osseous defects includes a native and/or renatured collagen matrix of congregated collagen chains, in which essentially only a surface of the congregated collagen chains is mineralized. A shaped article for filling osseous defects includes such a material. A method for producing a shaped article for filling osseous defects from a liquid medium, includes the steps of deposition of a mineral substance, preferably from its dissolved ionogenic components, on a collagen matrix, precipitation of the mineralized collagen matrix, separation of the mineralized collagen matrix, transfer of the mineralized collagen matrix to a suspension, transfer of the suspension to a mold defining the shaped article, and freeze-drying of the suspension in the mold.
    Type: Application
    Filed: November 22, 2005
    Publication date: August 27, 2009
    Inventors: Marco Springer, Arne Briest
  • POROUS AND BIOCOMPATIBLE CARRIER MATERIAL FOR TREATING BONE AND/OR CARTILAGE DEFECTS
    Publication number: 20090022773
    Abstract: A porous and biocompatible carrier material for treating bone and/or cartilage defects, including a collagen of animal origin that has an active substance complex.
    Type: Application
    Filed: December 1, 2006
    Publication date: January 22, 2009
    Applicant: Ossacur AG, a corporation of Germany a corporation of Germany
    Inventors: Marco Springer, Arne Briest
  • GELATINOUS MATERIAL FOR FILLING BONE AND/OR CARTILAGE DEFECTS
    Publication number: 20090017093
    Abstract: Disclosed is a goal gel-type material for filling bone and/or cartilage defects. Said gel-type material comprises at least one gelatinizing component and collagen in at least one liquid dispersing agent. The collagen contains an active substance complex. Preferably, the inventive material is provided with osteoconductive and osteoinductive properties.
    Type: Application
    Filed: December 22, 2005
    Publication date: January 15, 2009
    Inventors: Marco Springer, Arne Briest